
Mark Roschewski/LinkedIn
Aug 15, 2025, 14:48
Mark Roschewski: Precise Remission Assessment in LBCL Using PhasED-Seq ctDNA
Mark Roschewski, Senior Clinician at National Cancer Institute (NCI), shared on X:
“Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma | Journal of Clinical Oncology
Read this paper which shows that ctDNA MRD by PhasED-Seq is the most precise way to define a remission after therapy for LBCL.”
Title: Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma
Authors: Mark Roschewski, David M. Kurtz, Jason R. Westin, Ryan C. Lynch, Ajay K. Gopal, Stefan K. Alig, Brian J. Sworder, Hua-Jay J. Cherng, Christian Kuffer, Derek Blair, Krystal Brown, Jordan S. Goldstein, Andre Schultz, Sandra Close, Jacob J. Chabon, Maximilian Diehn, Wyndham H. Wilson, Ash A. Alizadeh
More posts featuring Large B-cell Lymphoma.
Ajay K. Gopal
Andre Schultz
Ash A. Alizadeh
B-cell lymphoma
Brian J. Sworder
cancer
Christian Kuffer
David M. Kurtz
Derek Blair
Hua-Jay J Cherng
Jacob J. Chabon
Jason R. Westin
Jordan S. Goldstein
Krystal Brown
LBCL
Mark Roschewski
Maximilian Diehn
National Cancer Institute
OncoDaily
Oncology
Ryan C. Lynch
Sandra Close
Stefan K. Alig
Wyndham H. Wilson
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 15, 2025, 14:48
Aug 15, 2025, 14:41
Aug 15, 2025, 14:31
Aug 15, 2025, 14:13
Aug 15, 2025, 13:48
Aug 15, 2025, 13:32